ARGNF News and Press, Argen X NV From 10/31/23

$329 million in third quarter global net product sales On track to submit VYVGART ® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host conference call today at 1:30 pm CET (8:30 am ET) ...

2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...

2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...

October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Tuesday, ...

2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...

2023-10-22 08:20:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy held up b...

2023-10-19 01:20:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the health care industry. The Fund trailed the Benchmark by 217 basis points this quarte...

VYVGART Ⓡ is the first-and-only neonatal Fc receptor ( FcRn ) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0 0 01) showing 68% of VYVGART-treated patients wer...

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administration European Commission (EC) decision on marketing authorization applica...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...